Dr Habeebullah Life Sciences Ltd (DRHABEEB) along with its group Companies has established platforms in the areas of
Stem Cell Research and Therapy:
This division, a part of the group Company is specialized in Stem Cell Research & Therapy, Regenerative Medicine, Bio-artificial organ scaffolds development, nanobiotechnology, Nanoformulation of cancer Drugs, Molecular genetics, and Molecular virology, Stem cell and Cord blood banking while simultaneously imparting advanced learning aimed at expanding and adding to the body of scientific knowledge. Through a transparent structure, the Research Unit will focus on R&D in stem cells and therapy through the Origin Hospital. The Stem Cell therapy focuses on the body organs of Liver, Pancreas, Neural, cardiac, Vascular, Renal and Ortho. The focus is mainly on stem cell therapy for end stage diseases and development of novel strategies for disease prognosis and treatment.
New Drug Discovery:
This division is a part of the Subsidiary Company, Krisani BioSciences Pvt Ltd, with focus on large unmet medical and market needs with reduced risk and high reward molecules. The division is currently working on 5 therapeutic areas of Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease and has been granted 11 international patents. Most of the above molecules have the ability to qualify for 505(b) 2 approval process as per USFDA. Adopting the concept of prodrug and selection of orphan drugs enables Less time frame, cost, and regulatory hurdles in comparison with New Chemical Entities.
The new drug discovery and development process of Dr Habeebullah Life Sciences is based on IP protected, low risk innovative platform. This, coupled with the strategy of selecting orphan drug category for the product portfolio gives the Company an added advantage to commercialize its NME’s at a proof-of-concept stage.
Molecular Prognosis and Diagnostics services:
This division is currently providing molecular diagnostics and services in the areas of Cytogenetics, Pharmacogenomics, Pathalogy, Radiology, Hematology, Bio chemistry, Micro Biology and many more. The division has a Singapore patent granted for RNA based molecular diagnostics kit. Innovative bio markers in DNA, RNA, miRNA and kits are under development.
CRO:
Habeebullah Life Sciences’s group Company has the technical expertise and infrastructure to deliver diverse chemistries from gram to kilogram scale. This enables the Company to partner with biotech and pharma companies throughout the lifecycle of the product. Apart from routine organic chemical transformations, the division’s chemistry range includes: Multi-step synthesis, Cryogenic reactions, heterocyclic chemistry, Suzuki Coupling, Heck coupling, Sonogashira coupling, Amide Coupling, Nitrations, Chlorinations, Sodium metal handling, Diazotization, Chiral Chemistry.
Stem Cell focused Super Specialty Hospital:
This division is currently in the trial run phase since July 2017. The Company plans to launch the full-fledged services from Jan 2018 with its focus areas for treatment being Gastroenterology, Neurology, Cardiology, Radiology, Nephrology, Orthopedics, Oncology, Urology, Pulmonology and Gynecology.
RNA Interference Technology:
This division established a unique model of developing new panel of miRNAs as a novel Bio Marker and file the patent as an innovative Kit. It involves synergistically conjugating the modified miRNAs with existing drugs forming prodrugs and later filing the patents as NMEs.
Medical Devices:
The medical devices division is effortlessly working towards efficient management of chronic diseases through development of extra-corporeal liver support device for the management of acute liver failure, Bioengineering implantable humanized nerve conduits for spinal cord injury, development of implantable nanochips carrying insulin producing cells for the management of uncontrolled diabetes mellitus, development of extra-corporeal device for the removal of circulating tumor cells(CTCs) from cancer patients and sepsis removal using nanotechnology-based extracorporeal device.